RxDoctor Payments DataLook up a doctor →

John Adams, MD

Urology · Germantown, TNNPI 1962469023

Payments from drug & device makers

$13,825in general payments, 2019–2025

Across 629 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$1K
  • Sumitomo Pharma America, Inc.$1K
  • Astellas Pharma US Inc$1K
  • Urogen Pharma, Inc.$1K
  • Johnson & Johnson$980
  • Bayer$815
  • plus $7K from 51 others

What the payments were for

  • Food & beverage$13,65999%
  • Education$1661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,825 in reported general payments places this provider in the 75th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$915,899
Medicare patients
1,128
Services billed
106,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix40$106,066
GemtesaVibegron102$85,012
MyrbetriqMirabegron60$42,451
Testosterone48$12,394
Tamsulosin Hcl676$11,360
XyostedTestosterone Enanthate13$7,568
Solifenacin Succinate121$6,909
Potassium Citrate ErPotassium Citrate76$6,329
Finasteride234$3,541
Bethanechol Chloride42$2,912
Alfuzosin Hcl ErAlfuzosin Hcl132$2,675
Silodosin18$2,632
Dutasteride78$2,056
Amiloride-HydrochlorothiazideAmiloride/Hydrochlorothiazide47$1,850
Allopurinol131$1,341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$1,327$191,078142 claims
Astellas Pharma US IncMyrbetriq$1,232$42,45160 claims
Antares Pharma, Inc.Xyosted$133$7,56813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 276 urology providers in Tennessee.

Other urology in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →